Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer

Phase 3

Completed

• Conditions: Adenocarcinoma of the Colon
• Interventions: Drug: Tinzaparin

• Registration Number: NCT01455831
• Lead Sponsor: Ottawa Hospital Research Institute

Brief Summary

The human body has a natural stress response to surgery, including the formation of blood clots. This response to surgery has been shown to increase metastases (the spread of cancer cells to other organs in the body). These metastases cannot be seen at the time of surgery but when they grow into new tumors, the cancer has recurred (come back). A blood thinner called "low molecular weight heparin" (LMWH) can suppress the development of metastases after surgery in animal experiments. The investigators want to see if giving patients with colorectal cancer the blood thinner, LMWH, around the time of surgery can decrease the chance of their cancer spreading to other organs (metastases) and coming back (recurrence).

The investigators need 1075 patients to answer our scientific question. Patients who give informed consent will be randomly put into one of two groups, the experimental group and the control group. The patients in the control group will be treated with LMWH starting a few hours after surgery and every day until they leave the hospital. This is how most patients are treated after colon cancer surgery (standard care). The patients in the experimental group will be treated with LMWH for a longer period of time, starting on the day they agree to have surgery and continuing for two months after surgery. All the patients will be followed for at least three years after surgery to find out if their cancer has recurred (come back). If LMWH treatment around the time of surgery reduces the chance of recurrence in patients with colorectal cancer, it would improve the health and quality of life for these patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-09
• Study First Submitted: 2011-10-18
• Study First Submitted QC: 2011-10-19
• Study First Posted: 2011-10-20
• Primary Completion: 2020-12-31
• Study Completion: 2021-02-01
• Status Verified: 2021-05
• Last Update Submitted: 2021-05-14
• Last Update Posted: 2021-05-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 616

Inclusion Criteria

1. Diagnosis of pathologically-confirmed invasive adenocarcinoma of the colon or rectum
2. Pre-operative work-up that reveals potential resectability (CT scan or MRI of the abdomen and pelvis) with resection planned within 6 weeks of date of randomization
3. Pre-operative work-up that reveals no evidence of metastatic disease (CT scan or MRI of the abdomen and pelvis and chest X-ray (CXR) or CT scan of the chest)
4. Age ≥18 years
5. Hemoglobin ≥ 80g/L
6. Able and willing to comply with study procedures and follow-up examinations contained within the written consent form.

Read More

Exclusion Criteria

1. Carcinoma only present in a completely excised polyp (i.e. no residual tumour evident in the colon)

2. Prior VTE including deep vein thrombosis (DVT) or pulmonary embolism (PE)

3. Requirement for full dose peri-operative anticoagulation

4. Contraindication to heparin therapy

   1. history of heparin induced thrombocytopenia (HIT)
   2. platelet count of less than 100 x 109/L
   3. actively bleeding
   4. severe hypertension (SBP >200 and/or DBP >120) on more than one reading
   5. documented peptic ulcer within 6 weeks
   6. severe hepatic failure (INR >1.8)
   7. creatinine clearance of < 30 ml/min as calculated by the Cockcroft-Gault formula
   8. Other contraindication to anticoagulation

5. Participating in another interventional trial that may result in co-intervention or contamination (to be determined by sponsor)

6. History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within 5 years of the colorectal cancer diagnosis

7. Pregnant or lactating

8. Unable/unwilling to providing informed consent.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Extended peri-operative thromboprophylaxis	Tinzaparin	The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
Standard thromboprophylaxis	Tinzaparin	The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.

Primary Outcome Measures

Name	Time	Method
Disease Free Survival	measured at 3 years	Disease free survival is measured from the time of randomization until local disease recurrence, distant disease recurrence, a new primary colon cancer malignancy, other second primary cancer or death from any cause.

Secondary Outcome Measures

Name	Time	Method
Overall Survival	measured at 5 years	Death from any cause
Venous Thromboembolism events	From randomization until 56 days post-surgery	• VTE events defined as: a. Deep vein thrombosis: i. non-compressibility of any vein segment from the common femoral vein to the trifurcation of the popliteal vein on compressive ultrasonography ii.persistent intra-luminal filling defect of the iliac, common femoral, superficial femoral, popliteal, posterior tibial or peroneal veins on contrast venography b. Pulmonary embolism: i.high probability V/Q scan ii.positive pulmonary angiogram iii.spiral CT demonstrating intraluminal filling defect in a vessel larger than a segmental artery
Major surgical site bleeding events	From randomization until 56 days post-surgery	• Major surgical site bleeding events defined as bleeding at the surgical site associated with: 1. requirement for ≥4 units of packed red blood cells; 2. a drop in Hb of \>40 g/L during the first post-op week; 3. bleeding requiring re-operation; 4. fatal bleeding
Major bleeding events (not including the surgical site)	From randomization until 56 days post-surgery	• Major bleeding events (not including the surgical site) defined as: 1. fatal bleeding, and/or; 2. symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or,; 3. bleeding causing a fall in hemoglobin level of ≥20 g/L, or leading to transfusion of ≥2 units of whole blood or red cells.
• Clinically relevant bleeding events prior to surgery and during the • Clinically relevant bleeding events	From randomization to 56 days post-surgery	Clinically relevant bleeding events prior to surgery and during the follow-up period will be defined as overt bleeding episodes not meeting the inclusion for major bleeding but associated with one of the following: 1. medical intervention; 2. an unscheduled contact with a physician; 3. temporary cessation of anticoagulant treatment
Transfusion requirements	From randomization to 56 days post-surgery	Transfusion requirements using the number of units transfused: 1. Red blood cells; 2. Platelets (Adult dose); 3. Frozen Plasma
Correlative endpoints	5 years	The correlative endpoints seek to evaluate the pro-metastatic mechanisms of surgery and the antimetastatic mechanisms of LMWH in subjects undergoing surgical resection for colon cancer.
Other post-operative (day 0 - day 28) complications	Measured from Day 0 until day 28 post-operatively	Other post-operative (day 0 - day 28) complications as defined using the modified Clavien Classification

Trial Locations

Locations (16)

Ghent University Hospital; 🇧🇪 Ghent, Belgium

Jewish General Hospital; 🇨🇦 Montreal, Quebec, Canada

Hamilton Health Sciences Corporation; 🇨🇦 Hamilton, Ontario, Canada

London Health Research Institute; 🇨🇦 London, Ontario, Canada

The Ottawa Hospital; 🇨🇦 Ottawa, Ontario, Canada

Montfort Hospital; 🇨🇦 Ottawa, Ontario, Canada

Queensway Carleton Hospital; 🇨🇦 Ottawa, Ontario, Canada

Sault Area Hospital; 🇨🇦 Sault Ste. Marie, Ontario, Canada

Health Sciences North; 🇨🇦 Sudbury, Ontario, Canada

Mount Sinai Hospital; 🇨🇦 Toronto, Ontario, Canada

Sunnybrook Health Science Centre; 🇨🇦 Toronto, Ontario, Canada

CHRU Brest; 🇫🇷 Brest, France

Kingston General Hospital; 🇨🇦 Kingston, Ontario, Canada

Humber River Hospital; 🇨🇦 Toronto, Ontario, Canada

North York General Hospital; 🇨🇦 Toronto, Ontario, Canada

St. Joseph's Health Centre; 🇨🇦 Toronto, Ontario, Canada